The most recent analyst rating on (CRBP) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.

On this episode of Asking for Trend, Host Josh Lipton breaks down some of the biggest takeaways and trends of the trading day. Wall Street was rocked on Monday as US equities (^GSPC, ^DJI, ^IXIC) were ...

RBC Capital Markets reduced its S&P 500 (^GSPC) year-end target to 6,200 from 6,600, while investors search for indicators that the market (^DJI, ^IXIC, ^GSPC) has finally bottomed out. Yahoo Finance ...

CBRE Group (CBRE) reported the first increase in real estate transaction volume in over two years during the third quarter of 2024. Janus Henderson Investors portfolio manager of global real estate ...

The study involves administering CRB-601 alone or in combination with anti-PD-1 therapy ... with its primary completion and estimated completion dates yet to be announced. The latest update was ...

The Federal Court has upheld the denial of Canada Recovery Benefit (CRB) due to insufficient evidence and the applicant's failure to attend the hearing. In Li v. Canada (Attorney General), 2024 FC ...

US housing starts rose 1.6% in April, while construction on multi-family buildings surged ahead by over 10%. Zillow Group Senior Economist Orphe Divounguy sits down with Brad Smith to talk more about ...

The government has had to cancel at least $246 million in debts for thousands of Canadians it initially claimed had received pandemic benefits for which they weren't eligible. Since 2022, the Canada ...